Literature DB >> 19588521

Vincristine: Can its therapeutic index be enhanced?

Andrew Moore1, Ross Pinkerton.   

Abstract

Vincristine is one of the most widely used and more effective drugs in paediatric oncology. The dose-limiting toxicity of neuropathy, lack of proven neuroprotective measures and an incomplete understanding of the pharmacokinetics and pharmacogenetics of vincristine have limited its therapeutic potential. Recent advances in the understanding of vincristine pharmacokinetics and pharmacogenetics, and potential methods of preventing neurotoxicity are reviewed which could enable dose escalation and dose individualisation in order to enhance the therapeutic index. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19588521     DOI: 10.1002/pbc.22161

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  26 in total

Review 1.  Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.

Authors:  Brad Moriyama; Stacey A Henning; Janice Leung; Oluwaseun Falade-Nwulia; Paul Jarosinski; Scott R Penzak; Thomas J Walsh
Journal:  Mycoses       Date:  2011-11-29       Impact factor: 4.377

2.  Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy.

Authors:  Laurence Meyer; Christine Patte-Mensah; Omar Taleb; Ayikoe Guy Mensah-Nyagan
Journal:  Cell Mol Life Sci       Date:  2010-04-30       Impact factor: 9.261

Review 3.  The two faces of FBW7 in cancer drug resistance.

Authors:  Zhiwei Wang; Hidefumi Fukushima; Daming Gao; Hiroyuki Inuzuka; Lixin Wan; Alan W Lau; Pengda Liu; Wenyi Wei
Journal:  Bioessays       Date:  2011-08-30       Impact factor: 4.345

4.  Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma.

Authors:  Jason Kato; Yuanpei Li; Kai Xiao; Joyce S Lee; Juntao Luo; Joseph M Tuscano; Robert T O'Donnell; Kit S Lam
Journal:  Mol Pharm       Date:  2012-05-01       Impact factor: 4.939

5.  Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.

Authors:  Bryan Langholz; Jeffrey M Skolnik; Jeffrey S Barrett; Jamie Renbarger; Nita L Seibel; Anne Zajicek; Carola A S Arndt
Journal:  Pediatr Blood Cancer       Date:  2010-12-01       Impact factor: 3.167

6.  An overlooked complication of vancomycin induced acute flaccid paralysis in a child with acute leukemia: a case report.

Authors:  Khalid Al Alawi; Mohammed Al Shinawy; Aqeela Taqee; Yasser Wali
Journal:  Oman Med J       Date:  2011-07

7.  Neuropathic pain during treatment for childhood acute lymphoblastic leukemia.

Authors:  Doralina L Anghelescu; Lane G Faughnan; Sima Jeha; Mary V Relling; Pamela S Hinds; John T Sandlund; Cheng Cheng; Deqing Pei; Gisele Hankins; Jennifer L Pauley; Ching-Hon Pui
Journal:  Pediatr Blood Cancer       Date:  2011-02-11       Impact factor: 3.167

8.  The impact of recent vincristine on human hematopoietic progenitor cell collection in pediatric patients with central nervous system tumors.

Authors:  Laura Cooling; Melissa Bombery; Sandra Hoffmann; Robertson Davenport; Patricia Robertson; John E Levine
Journal:  Transfusion       Date:  2014-02-17       Impact factor: 3.157

9.  Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.

Authors:  James W Behan; Vassilios I Avramis; Jason P Yun; Stan G Louie; Steven D Mittelman
Journal:  Pharmacol Res       Date:  2010-01-18       Impact factor: 7.658

Review 10.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.